Altimmune Inc is a biopharmaceutical company based in Gaithersburg, Maryland, focusing on innovative treatments for obesity and liver diseases. Its leading product, pemvidutide, is a promising obesity and non-alcoholic steatohepatitis treatment currently in Phase 2 trials. Additionally, Altimmune is developing HepTcell, aimed at treating chronic hepatitis B virus infections, also in Phase 2 trials. Founded in 1997 and originally named Vaxin Inc., the company rebranded to Altimmune Inc in 2015, continuing its mission to address critical unmet medical needs.
Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit. The clinical-stage biotech develops treatments for metabolic diseases and became one…
Short interest is always a sign of how bearish investors may be on a stock. But it can also serve as a potential sign of a coming short squeeze, especially if the…
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction), for example. Now trading at $57.80, we strongly believe it…
Thursday’s additional top analyst upgrades and downgrades were on Ally Financial, Altimmune, Capital One Financial, GoodRx, Leslie’s, PagSeguro Digital, Regions Financial, Sirius XM, StoneCo, Tencent Music Entertainment and more.
Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Wednesday's top analyst upgrades and downgrades included Alphabet, Canopy Growth, Cinemark, Dick's Sporting Goods, Facebook, IMAX, Microsoft, Salesforce.com and SBA Communications.
Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Chris Lange Thursday's top analyst upgrades and downgrades included Allstate, Bed Bath & Beyond, Simon Property, Spirit Airlines, Twitter and Under Armour.
Altimmune shares dropped on Thursday after the company announced that it had received an update from the FDA regarding its COVID-19 vaccine candidate.
Chris Lange Altimmune made a step forward on Tuesday with its vaccine candidate for COVID-19. Specifically, the firm entered into a manufacturing agreement the vaccine candidate.
Chris Lange Altimmune made some progress with its COVID-19 treatment on Monday after it announced some new funding for its trials.
Chris Lange 24/7 Wall St. has tracked some stocks that either are defensive in general or are defying Monday's big drop because they have some aspect of their business that might be immune to…
Altimmune shares surged on Tuesday following results from its midstage study of a intranasal influenza vaccine candidate.
Chris Lange 
